DaVita Inc hits 52-week low amid market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 07 Jan 26
Source: NASDAQ.COM
DaVita Inc's stock price fell by 3.21% during regular trading, hitting a 52-week low. This decline occurs in a mixed market environment, with the Nasdaq-100 up 0.11% and the S&P 500 down 0.31%.
The drop in DaVita's stock price is attributed to broad market weakness, as the overall market sentiment has shifted despite some gains in the Nasdaq-100. This indicates a potential sector rotation, where investors may be reallocating their investments away from healthcare stocks like DaVita.
Investors are closely monitoring the company's performance and market trends, as the healthcare sector faces challenges amid changing investor preferences. The recent price movement may prompt further analysis of DaVita's strategic positioning in the market.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 136.50 USD with a low forecast of 130.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
3 Hold
1 Sell
Hold
Current: 105.880
Low
130.00
Averages
136.50
High
143.00
Current: 105.880
Low
130.00
Averages
136.50
High
143.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
